This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The main function of trypanothione synthase is to use the free energy generated from ATP hydrolysis to conjugate glutathione and spermidine to form the intermediate of glutathionylspermidine and then the final product of trypanothione. It also catalyzes the reverse reaction as well, albeit at a much lower rate. Under conditions found to be the optimum for both the forward and backwards reactions, trypanothione synthase from trypanosoma cruzi was found to have an amidase activity that was only about 1% of the forwards synthetase activity. This low activity can be explained by the blocking of the catalytic Cys in the amidase active site in order for the protein to properly fold. In parasitic kinetoplastids trypanothione synthase activity is key to survival. Due to the need for trypanothione in order to defend against oxidative stresses, and maintain thiol and ribonucleotide metabolism. It was observed that induced knockout of trypanothione synthase through RNA interference caused a reduced growth rate of twofold among trypanosoma brucei due to the immediate disruption of flux through thiol redox. In other similar experiments which observed cell death after knocking out trypanothione synthase, it was shown that after two hours of being exposed to hydrogen peroxide in order to mimic the oxidant attack of phagocytes, the cells which did not contain working trypanothione synthase had a much higher death rate than wild type T. brucei.
=== Protein assembly === After initiation, elongation, and termination, there is a fourth step of the disassembly of the post-termination complex of ribosome, mRNA, and tRNA, which is a prerequisite for the next round of protein synthesis. The large ribosomal subunit has a role in protein folding both in vitro and in vivo. The large ribosomal subunit provides a hydrophobic surface for the hydrophobic collapse step of protein folding. The newly synthesized protein needs full access to the large subunit to fold; this process may take a period of time (5 minutes for beta-galactosidase).
At Nagapatnam, Pulicat, and elsewhere, the company purchased 8,000–10,000 slaves, the bulk of whom were sent to Ceylon, while a small portion were exported to Batavia and Malacca. Finally, following a long drought in Madurai and southern Coromandel, in 1673, which intensified the prolonged Madurai-Maratha struggle over Tanjavur and punitive fiscal practices, thousands of people from Tanjavur, mostly children, were sold into slavery and exported by Asian traders from Nagapattinam to Aceh, Johor, and other slave markets. In September 1687, 665 slaves were exported by the English from Fort St. George, Madras. And, in 1694–96, when warfare once more ravaged South India, a total of 3,859 slaves were imported from Coromandel by private individuals into Ceylon. The volume of the total Dutch Indian Ocean slave trade has been estimated to be about 15–30% of the Atlantic slave trade, slightly smaller than the trans-Saharan slave trade, and one-and-a-half to three times the size of the Swahili and Red Sea coast and the Dutch West India Company slave trades. According to Sir Henry Bartle Frere (who sat on the Viceroy's Council), there were an estimated 8 or 9 million slaves in India in 1841. About 15% of the population of Malabar were slaves. Slavery was legally abolished in the possessions of the East India Company by the Indian Slavery Act, 1843.
== Participation in the creation-evolution debate == Wickramasinghe and his mentor Fred Hoyle have also used their data to argue in favor of cosmic ancestry, and against the idea of life emerging from inanimate objects by abiogenesis.
The trust's executive directors discussed involving the police but instead commissioned a review by the Royal College of Paediatrics and Child Health (RCPCH). Letby was taken off the unit on 30 June, and the hospital subsequently reduced cot capacity and raised the gestational‑age threshold for admissions. The RCPCH review began in September 2016. Its October report found no definitive explanation for the increased mortality rate but identified inadequate staffing and senior cover. It described concerns about Letby as subjective and unsupported by evidence. The trust's medical director asked consultant neonatologist Jane Hawdon to undertake detailed case reviews recommended by the RCPCH. Hawdon instead conducted a review of medical notes relating to 17 deaths and collapses; she was understood to have told the hospital's medical director that she had not been able to conduct the thorough review that the RCPCH had recommended due to not having had the time, and later said that she had not been "adequately briefed" about the concerns about Letby before she carried out her analysis. The report concluded that most of the deaths and collapses could be explained and might have been preventable with different care, while four warranted further local forensic review. Minutes of a subsequent board meeting recorded the medical director stating that the RCPCH and Hawdon reviews attributed the deaths to leadership and intervention issues; the board chair later said he had been misled about the depth of Hawdon's review.
Sources: en.wikipedia.org
=== GABAergic signaling === One mechanism through which BDNF appears to maintain elevated levels of neuronal excitation is through preventing GABAergic signaling activities. While glutamate is the brain's major excitatory neurotransmitter and phosphorylation normally activates receptors, GABA is the brain's primary inhibitory neurotransmitter and phosphorylation of GABAA receptors tend to reduce their activity. Blockading BDNF signaling with a tyrosine kinase inhibitor or a PKC inhibitor in wild type mice produced significant reductions in spontaneous action potential frequencies that were mediated by an increase in the amplitude of GABAergic inhibitory postsynaptic currents (IPSC). Similar effects could be obtained in BDNF knockout mice, but these effects were reversed by local application of BDNF. This suggests BDNF increases excitatory synaptic signaling partly through the post-synaptic suppression of GABAergic signaling by activating PKC through its association with TrkB. Once activated, PKC can reduce the amplitude of IPSCs through to GABAA receptor phosphorylation and inhibition. In support of this putative mechanism, activation of PKCε leads to phosphorylation of N-ethylmaleimide-sensitive factor (NSF) at serine 460 and threonine 461, increasing its ATPase activity which downregulates GABAA receptor surface expression and subsequently attenuates inhibitory currents.
The melanocortin 1 receptor (MC1R), also known as melanocyte-stimulating hormone receptor (MSHR), melanin-activating peptide receptor, or melanotropin receptor, is a G protein–coupled receptor that binds to a class of pituitary peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH) and the different forms of melanocyte-stimulating hormone (MSH). It is coupled to Gαs and upregulates levels of cAMP by activating adenylyl cyclase in cells expressing this receptor. It is normally expressed in skin and melanocytes, and to a lesser degree in periaqueductal gray matter, astrocytes and leukocytes. In skin cancer, MC1R is highly expressed in melanomas but not carcinomas. MC1R is one of the key proteins involved in regulating mammalian skin color and hair color. It is located on the plasma membrane of specialized cells known as melanocytes, which produce the pigment melanin through the process of melanogenesis. It controls the type of melanin being produced, and its activation causes the melanocyte to switch from generating the yellow-red phaeomelanin by default to the brown-black eumelanin in replacement. In humans, a number of loss-of-function mutations of MC1R have been described, with redheads often having multiple individual loss-of-function mutations, but as of 2001, activating mutations that increase eumelanin synthesis have not been described. MC1R has also been reported to be involved in cancer (independent of skin coloration), developmental processes, and susceptibility to infections and pain.
=== MB-003 === MB-003 is a cocktail of three humanized or human–mouse chimeric mAbs: c13C6, h13F6, and c6D8. A study published in September 2012 found that rhesus macaques infected with Ebola virus (EBOV) survived when receiving MB-003 (mixture of 3 chimeric monoclonal antibodies) one hour after infection. When treated 24 or 48 hours after infection, four of six animals survived and had little to no viremia and few, if any, clinical symptoms. MB-003 was created by scientists at the U.S. Army Medical Research Institute of Infectious Diseases, Gene Olinger, and Jamie Pettitt in collaboration with Mapp Biopharmaceutical with years of funding from US government agencies including the National Institute of Allergy and Infectious Disease, Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency.
=== Higher-calorie variants === In extreme cold temperatures, the packaged wet food in MREs can freeze solid, rendering the food inedible and the heating packet insufficient. The Meal, Cold Weather (MCW) provides a ration similar to the MRE designed for lower temperatures than the MRE can withstand. Clad in white packaging, it offers a freeze-dried entree designed to be eaten with heated water, the same side ingredients as the standard MRE, and additional drink mixes to encourage additional hydration. The caloric and fat content of the meals is also increased. The MCW replaced the Ration, Cold Weather (RCW). The Meal, Long Range Patrol (LRP) is essentially the same as the MCW, but with different accessory packs. The MLRP is designed for troops who may receive limited or no supply, and weight of the ration is critical. The similar First Strike Ration is along the same lines, but requires no preparation and may be eaten on the go.
=== EC 2.4.1: Hexosyltransferases === EC 2.4.1.1: Glycogen phosphorylase EC 2.4.1.2: dextrin dextranase EC 2.4.1.3: deleted, included in EC 2.4.1.25 EC 2.4.1.4: amylosucrase EC 2.4.1.5: dextransucrase EC 2.4.1.6: deleted EC 2.4.1.7: sucrose phosphorylase EC 2.4.1.8: maltose phosphorylase EC 2.4.1.9: inulosucrase EC 2.4.1.10: levansucrase EC 2.4.1.11: glycogen(starch) synthase EC 2.4.1.12: cellulose synthase (UDP-forming) EC 2.4.1.13: sucrose synthase EC 2.4.1.14: sucrose-phosphate synthase EC 2.4.1.15: α,α-trehalose-phosphate synthase (UDP-forming) EC 2.4.1.16: chitin synthase EC 2.4.1.17: glucuronosyltransferase EC 2.4.1.18: ,4-α-glucan branching enzyme EC 2.4.1.19: cyclomaltodextrin glucanotransferase EC 2.4.1.20: cellobiose phosphorylase EC 2.4.1.21: starch synthase EC 2.4.1.22: lactose synthase EC 2.4.1.23: sphingosine β-galactosyltransferase EC 2.4.1.24: 1,4-α-glucan 6-α-glucosyltransferase EC 2.4.1.25: 4-α-glucanotransferase EC 2.4.1.26: DNA α-glucosyltransferase EC 2.4.1.27: DNA β-glucosyltransferase EC 2.4.1.28: glucosyl-DNA β-glucosyltransferase EC 2.4.1.29: cellulose synthase (GDP-forming) EC 2.4.1.30: 1,3-β-oligoglucan phosphorylase EC 2.4.1.31: laminaribiose phosphorylase EC 2.4.1.32: glucomannan 4-β-mannosyltransferase EC 2.4.1.33: mannuronan synthase EC 2.4.1.34: 1,3-β-glucan synthase EC 2.4.1.35: phenol β-glucosyltransferase EC 2.4.1.36: α,α-trehalose-phosphate synthase (GDP-forming) EC 2.4.1.37: fucosylgalactoside 3-α-galactosyltransferase EC 2.4.1.38: β-N-acetylglucosaminylglycopeptide β-1,4-galactosyltransferase EC 2.4.1.39: steroid N-acetylglucosaminyltransferase EC 2.4.1.40: glycoprotein-fucosylgalactoside α-N-acetylgalactosaminyltransferase EC 2.4.1.41: polypeptide N-acetylgalactosaminyltransferase EC 2.4.1.42: deleted, included in EC 2.4.1.17 EC 2.4.1.43: polygalacturonate 4-α-galacturonosyltransferase EC 2.4.1.44: lipopolysaccharide 3-α-galactosyltransferase EC 2.4.1.45: now included with EC 2.4.1.47, N-acylsphingosine galactosyltransferase EC 2.4.1.46: monogalactosyldiacylglycerol synthase EC 2.4.1.47: N-acylsphingosine galactosyltransferase EC 2.4.1.48: heteroglycan α-mannosyltransferase EC 2.4.1.49: cellodextrin phosphorylase EC 2.4.1.50: procollagen galactosyltransferase EC 2.4.1.51: now covered by EC 2.4.1.101, EC 2.4.1.143, EC 2.4.1.144 and EC 2.4.1.145 EC 2.4.1.52: poly(glycerol-phosphate) α-glucosyltransferase EC 2.4.1.53: poly(ribitol-phosphate) β-glucosyltransferase EC 2.4.1.54: undecaprenyl-phosphate mannosyltransferase EC 2.4.1.55: Now EC 2.7.8.14, CDP-ribitol ribitolphosphotransferase EC 2.4.1.56: lipopolysaccharide N-acetylglucosaminyltransferase EC 2.4.1.57: Newer studies have shown that this is catalysed by two independent activities now covered by EC 2.4.1.345, phosphatidyl-myo-inositol α-mannosyl transferase and EC 2.4.1.346, phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.58: lipopolysaccharide glucosyltransferase I EC 2.4.1.59: deleted, included in EC 2.4.1.17 EC 2.4.1.60: CDP-abequose:α-D-Man-(1→4)-α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.61: deleted, included in EC 2.4.1.17 EC 2.4.1.62: ganglioside galactosyltransferase EC 2.4.1.63: linamarin synthase EC 2.4.1.64: α,α-trehalose phosphorylase EC 2.4.1.65: 3-galactosyl-N-acetylglucosaminide 4-α-L-fucosyltransferase EC 2.4.1.66: procollagen glucosyltransferase EC 2.4.1.67: galactinol—raffinose galactosyltransferase EC 2.4.1.68: glycoprotein 6-α-L-fucosyltransferase EC 2.4.1.69: type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.70: poly(ribitol-phosphate) α-N-acetylglucosaminyltransferase EC 2.4.1.71: arylamine glucosyltransferase EC 2.4.1.72: now EC 2.4.2.24, 1,4-β-D-xylan synthase EC 2.4.1.73: lipopolysaccharide glucosyltransferase II EC 2.4.1.74: glycosaminoglycan galactosyltransferase EC 2.4.1.75: deleted entry, insufficient evidence to conclude that this is a different enzyme from EC 2.4.1.43 EC 2.4.1.76: deleted, included in EC 2.4.1.17 EC 2.4.1.77: deleted, included in EC 2.4.1.17 EC 2.4.1.78: phosphopolyprenol glucosyltransferase EC 2.4.1.79: globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.80: ceramide glucosyltransferase EC 2.4.1.81: flavone 7-O-β-glucosyltransferase EC 2.4.1.82: galactinol—sucrose galactosyltransferase EC 2.4.1.83: dolichyl-phosphate β-D -mannosyltransferase EC 2.4.1.84: deleted, included in EC 2.4.1.17 EC 2.4.1.85: cyanohydrin β-glucosyltransferase EC 2.4.1.86: N-acetyl-β-D-glucosaminide β-(1,3)-galactosyltransferase EC 2.4.1.87: N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.88: globoside α-N-acetylgalactosaminyltransferase EC 2.4.1.89: deleted, included in EC 2.4.1.69, type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.90: N-acetyllactosamine synthase EC 2.4.1.91: flavonol 3-O-glucosyltransferase EC 2.4.1.92: (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase EC 2.4.1.93: Now EC 4.2.2.18, inulin fructotransferase (DFA-III-forming) EC 2.4.1.94: protein N-acetylglucosaminyltransferase EC 2.4.1.95: deleted EC 2.4.1.96: sn-glycerol-3-phosphate 1-galactosyltransferase EC 2.4.1.97: 1,3-β-D-glucan phosphorylase EC 2.4.1.98: deleted, Now included with EC 2.4.1.90, N-acetyllactosamine synthase EC 2.4.1.99: sucrose:sucrose fructosyltransferase EC 2.4.1.100: 2,1-fructan:2,1-fructan 1-fructosyltransferase EC 2.4.1.101: α-1,3-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.102: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.103: alizarin 2-β-glucosyltransferase EC 2.4.1.104: o-dihydroxycoumarin 7-O-glucosyltransferase EC 2.4.1.105: vitexin β-glucosyltransferase EC 2.4.1.106: isovitexin β-glucosyltransferase EC 2.4.1.107: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.108: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.109: dolichyl-phosphate-mannose—protein mannosyltransferase EC 2.4.1.110: tRNA-queuosine β-mannosyltransferase EC 2.4.1.111: coniferyl-alcohol glucosyltransferase EC 2.4.1.112: The protein referred to in this entry is now known to be glycogenin so the entry has been incorporated into EC 2.4.1.186, glycogenin glucosyltransferase EC 2.4.1.113: α-1,4-glucan-protein synthase (ADP-forming) EC 2.4.1.114: 2-coumarate O-β-glucosyltransferase EC 2.4.1.115: anthocyanidin 3-O-glucosyltransferase EC 2.4.1.116: cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.117: dolichyl-phosphate β-glucosyltransferase EC 2.4.1.118: cytokinin 7-β-glucosyltransferase EC 2.4.1.119: transferred to EC 2.4.99.18, dolichyl-diphosphooligosaccharideprotein glycotransferase EC 2.4.1.120: sinapate 1-glucosyltransferase EC 2.4.1.121: indole-3-acetate β-glucosyltransferase EC 2.4.1.122: N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.123: inositol 3-α-galactosyltransferase EC 2.4.1.124: Now EC 2.4.1.87, N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.125: sucrose—1,6-α-glucan 3(6)-α-glucosyltransferase EC 2.4.1.126: hydroxycinnamate 4-β-glucosyltransferase EC 2.4.1.127: monoterpenol β-glucosyltransferase EC 2.4.1.128: scopoletin glucosyltransferase EC 2.4.1.129: peptidoglycan glycosyltransferase EC 2.4.1.130: Now covered by EC 2.4.1.258, EC 2.4.1.259, EC 2.4.1.260 and EC 2.4.1.261 EC 2.4.1.131: GDP-Man:Man3GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.132: GDP-Man:Man1GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.133: xylosylprotein 4-β-galactosyltransferase EC 2.4.1.134: galactosylxylosylprotein 3-β-galactosyltransferase EC 2.4.1.135: galactosylgalactosylxylosylprotein 3-β-glucuronosyltransferase EC 2.4.1.136: gallate 1-β-glucosyltransferase EC 2.4.1.137: sn-glycerol-3-phosphate 2-α-galactosyltransferase EC 2.4.1.138: mannotetraose 2-α-N-acetylglucosaminyltransferase EC 2.4.1.139: maltose synthase EC 2.4.1.140: alternansucrase EC 2.4.1.141: N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase EC 2.4.1.142: chitobiosyldiphosphodolichol β-mannosyltransferase EC 2.4.1.143: α-1,6-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.144: β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.145: α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.146: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.147: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.148: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.149: N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.150: N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.151: now included with EC 2.4.1.87 N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.152: 4-galactosyl-N-acetylglucosaminide 3-α-L-fucosyltransferase EC 2.4.1.153: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminyltransferase EC 2.4.1.154: identical to EC 2.4.1.79, globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.155: α-1,6-mannosyl-glycoprotein 6-β-N-acetylglucosaminyltransferase EC 2.4.1.156: indolylacetyl-myo-inositol galactosyltransferase EC 2.4.1.157: 1,2-diacylglycerol 3-glucosyltransferase, now classified as EC 2.4.1.336, monoglucosyldiacylglycerol synthase, and EC 2.4.1.337, 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.158: 13-hydroxydocosanoate 13-β-glucosyltransferase EC 2.4.1.159: flavonol-3-O-glucoside L-rhamnosyltransferase EC 2.4.1.160: pyridoxine 5′-O-β-D-glucosyltransferase EC 2.4.1.161: oligosaccharide 4-α-D-glucosyltransferase EC 2.4.1.162: aldose β-D-fructosyltransferase EC 2.4.1.163: now included in EC 2.4.1.149, N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.164: now included with EC 2.4.1.150, N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.165: N-acetylneuraminylgalactosylglucosylceramide β-1,4-N-acetylgalactosaminyltransferase EC 2.4.1.166: raffinose—raffinose α-galactosyltransferase EC 2.4.1.167: sucrose 6F-α-galactosyltransferase EC 2.4.1.168: xyloglucan 4-glucosyltransferase EC 2.4.1.169: now EC 2.4.2.39, xyloglucan 6-xylosyltransferase EC 2.4.1.170: isoflavone 7-O-glucosyltransferase EC 2.4.1.171: methyl-ONN-azoxymethanol β-D-glucosyltransferase EC 2.4.1.172: salicyl-alcohol β-D-glucosyltransferase EC 2.4.1.173: sterol 3β-glucosyltransferase EC 2.4.1.174: glucuronylgalactosylproteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.175: glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.176: gibberellin β-D-glucosyltransferase EC 2.4.1.177: cinnamate β-D-glucosyltransferase EC 2.4.1.178: hydroxymandelonitrile glucosyltransferase EC 2.4.1.179: lactosylceramide β-1,3-galactosyltransferase EC 2.4.1.180: lipopolysaccharide N-acetylmannosaminouronosyltransferase EC 2.4.1.181: hydroxyanthraquinone glucosyltransferase EC 2.4.1.182: lipid-A-disaccharide synthase EC 2.4.1.183: α-1,3-glucan synthase EC 2.4.1.184: galactolipid galactosyltransferase EC 2.4.1.185: flavanone 7-O-β-glucosyltransferase EC 2.4.1.186: glycogenin glucosyltransferase EC 2.4.1.187: N-acetylglucosaminyldiphosphoundecaprenol N-acetyl-β-D-mannosaminyltransferase EC 2.4.1.188: N-acetylglucosaminyldiphosphoundecaprenol glucosyltransferase EC 2.4.1.189: uteolin 7-O-glucuronosyltransferase EC 2.4.1.190: luteolin-7-O-glucuronide 2′′-O-glucuronosyltransferase EC 2.4.1.191: luteolin-7-O-diglucuronide 4′-O-glucuronosyltransferase EC 2.4.1.192: nuatigenin 3β-glucosyltransferase EC 2.4.1.193: sarsapogenin 3β-glucosyltransferase EC 2.4.1.194: 4-hydroxybenzoate 4-O-β-D-glucosyltransferase EC 2.4.1.195: N-hydroxythioamide S-β-glucosyltransferase EC 2.4.1.196: nicotinate glucosyltransferase EC 2.4.1.197: high-mannose-oligosaccharide β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.198: phosphatidylinositol N-acetylglucosaminyltransferase EC 2.4.1.199: β-mannosylphosphodecaprenol—mannooligosaccharide 6-mannosyltransferase EC 2.4.1.200: now EC 4.2.2.17, inulin fructotransferase (DFA-I-forming) EC 2.4.1.201: α-1,6-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.202: 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase EC 2.4.1.203: trans-zeatin O-β-D-glucosyltransferase EC 2.4.1.204: now EC 2.4.2.40, zeatin O-β-D-xylosyltransferase EC 2.4.1.205: galactogen 6β-galactosyltransferase EC 2.4.1.206: lactosylceramide 1,3-N-acetyl-β-D-glucosaminyltransferase EC 2.4.1.207: xyloglucan:xyloglucosyl transferase EC 2.4.1.208: diglucosyl diacylglycerol synthase (1,2-linking) EC 2.4.1.209: cis-p-coumarate glucosyltransferase EC 2.4.1.210: limonoid glucosyltransferase EC 2.4.1.211: 1,3-β-galactosyl-N-acetylhexosamine phosphorylase EC 2.4.1.212: hyaluronan synthase EC 2.4.1.213: glucosylglycerol-phosphate synthase EC 2.4.1.214: glycoprotein 3-α-L-fucosyltransferase EC 2.4.1.215: cis-zeatin O-β-D-glucosyltransferase EC 2.4.1.216: trehalose 6-phosphate phosphorylase EC 2.4.1.217: mannosyl-3-phosphoglycerate synthase EC 2.4.1.218: hydroquinone glucosyltransferase EC 2.4.1.219: vomilenine glucosyltransferase EC 2.4.1.220: indoxyl-UDPG glucosyltransferase EC 2.4.1.221: peptide-O-fucosyltransferase EC 2.4.1.222: O-fucosylpeptide 3-β-N-acetylglucosaminyltransferase EC 2.4.1.223: glucuronosyl-galactosyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.224: glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.225: N-acetylglucosaminyl-proteoglycan 4-β-glucuronosyltransferase EC 2.4.1.226: N-acetylgalactosaminyl-proteoglycan 3-β-glucuronosyltransferase EC 2.4.1.227: undecaprenyldiphospho-muramoylpentapeptide β-N-acetylglucosaminyltransferase EC 2.4.1.228: lactosylceramide 4-α-galactosyltransferase EC 2.4.1.229: [Skp1-protein]-hydroxyproline N-acetylglucosaminyltransferase EC 2.4.1.230: kojibiose phosphorylase EC 2.4.1.231: α,α-trehalose phosphorylase (configuration-retaining) EC 2.4.1.232: initiation-specific α-1,6-mannosyltransferase EC 2.4.1.233: deleted: identical to EC 2.4.1.115, anthocyanidin 3-O-glucosyltransferase EC 2.4.1.234: kaempferol 3-O-galactosyltransferase EC 2.4.1.235: deleted: identical to EC 2.4.1.116, cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.236: flavanone 7-O-glucoside 2′′-O-β-L-rhamnosyltransferase EC 2.4.1.237: flavonol 7-O-β-glucosyltransferase EC 2.4.1.238: delphinidin 3,5-di-O-glucoside 3′-O-glucosyltransferase EC 2.4.1.239: flavonol-3-O-glucoside glucosyltransferase EC 2.4.1.240: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.241: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.242: NDP-glucose—starch glucosyltransferase EC 2.4.1.243: 6G-fructosyltransferase EC 2.4.1.244: N-acetyl-β-glucosaminyl-glycoprotein 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.245: α,α-trehalose synthase EC 2.4.1.246: mannosylfructose-phosphate synthase EC 2.4.1.247: β-D-galactosyl-(1→4)-L-rhamnose phosphorylase EC 2.4.1.248: cycloisomaltooligosaccharide glucanotransferase EC 2.4.1.249: delphinidin 3′,5′-O-glucosyltransferase EC 2.4.1.250: D-inositol-3-phosphate glycosyltransferase EC 2.4.1.251: GlcA-β-(1→2)-D-Man-α-(1→3)-D-Glc-β-(1→4)-D-Glc-α-1-diphospho-ditrans,octacis-undecaprenol 4-β-mannosyltransferase EC 2.4.1.252: GDP-mannose:cellobiosyl-diphosphopolyprenol α-mannosyltransferase EC 2.4.1.253: baicalein 7-O-glucuronosyltransferase EC 2.4.1.254: cyanidin-3-O-glucoside 2′′-O-glucuronosyltransferase EC 2.4.1.255: protein O-GlcNAc transferase EC 2.4.1.256: dolichyl-P-Glc:Glc2Man9GlcNAc2-PP-dolichol α-1,2-glucosyltransferase EC 2.4.1.257: GDP-Man:Man2GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.258: dolichyl-P-Man:Man5GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.259: dolichyl-P-Man:Man6GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.260: dolichyl-P-Man:Man7GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.261: dolichyl-P-Man:Man8GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.262: soyasapogenol glucuronosyltransferase EC 2.4.1.263: abscisate β-glucosyltransferase EC 2.4.1.264: D-Man-α-(1→3)-D-Glc-β-(1→4)-DD-Glc-α-1-diphosphoundecaprenol 2-β-glucuronosyltransferase EC 2.4.1.265: olichyl-P-Glc:Glc1Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.266: glucosyl-3-phosphoglycerate synthase EC 2.4.1.267: dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.268: glucosylglycerate synthase EC 2.4.1.269: mannosylglycerate synthase EC 2.4.1.270: mannosylglucosyl-3-phosphoglycerate synthase EC 2.4.1.271: crocetin glucosyltransferase EC 2.4.1.272: soyasapogenol B glucuronide galactosyltransferase EC 2.4.1.273: soyasaponin III rhamnosyltransferase EC 2.4.1.274: glucosylceramide β-1,4-galactosyltransferase EC 2.4.1.275: neolactotriaosylceramide β-1,4-galactosyltransferase EC 2.4.1.276: zeaxanthin glucosyltransferase EC 2.4.1.277: glycosyltransferase DesVII EC 2.4.1.278: desosaminyl transferase EryCIII EC 2.4.1.279: nigerose phosphorylase EC 2.4.1.280: N,N′-diacetylchitobiose phosphorylase EC 2.4.1.281: 4-O-β-D-mannosyl-D-glucose phosphorylase EC 2.4.1.282: 3-O-α-D-glucosyl-L-rhamnose phosphorylase EC 2.4.1.283: 2-deoxystreptamine N-acetyl-D-glucosaminyltransferase EC 2.4.1.284: 2-deoxystreptamine glucosyltransferase EC 2.4.1.285: UDP-GlcNAc:ribostamycin N-acetylglucosaminyltransferase EC 2.4.1.286: chalcone 4′-O-glucosyltransferase EC 2.4.1.287: rhamnopyranosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,4/1,5-galactofuranosyltransferase EC 2.4.1.288: galactofuranosylgalactofuranosylrhamnosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,5/1,6-galactofuranosyltransferase EC 2.4.1.289: N-acetylglucosaminyl-diphospho-decaprenol L-rhamnosyltransferase EC 2.4.1.290: N,N′-diacetylbacillosaminyl-diphospho-undecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.291: N-acetylgalactosamine-N,N′-diacetylbacillosaminyl-diphospho-undecaprenol 4-α-N-acetylgalactosaminyltransferase EC 2.4.1.292: GalNAc-α-(1→4)-GalNAc-α-(1→3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase EC 2.4.1.293: GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase EC 2.4.1.294: cyanidin 3-O-galactosyltransferase EC 2.4.1.295: anthocyanin 3-O-sambubioside 5-O-glucosyltransferase EC 2.4.1.296: anthocyanidin 3-O-coumaroylrutinoside 5-O-glucosyltransferase EC 2.4.1.297: anthocyanidin 3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.298: anthocyanidin 3-O-glucoside 5-O-glucosyltransferase EC 2.4.1.299: cyanidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose) EC 2.4.1.300: cyanidin 3-O-glucoside 7-O-glucosyltransferase (acyl-glucose) EC 2.4.1.301: 2′-deamino-2′-hydroxyneamine 1-α-D-kanosaminyltransferase EC 2.4.1.302: L-demethylnoviosyl transferase EC 2.4.1.303: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,3-galactosyltransferase EC 2.4.1.304: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,4-galactosyltransferase EC 2.4.1.305: UDP-Glc:α-D-GlcNAc-glucosaminyl-diphosphoundecaprenol β-1,3-glucosyltransferase EC 2.4.1.306: UDP-GalNAc:α-D-GalNAc-diphosphoundecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.307: UDP-Gal:α-D-GalNAc-1,3-α-D-GalNAc-diphosphoundecaprenol β-1,3-galactosyltransferase. Now included in EC 2.4.1.122, N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.308: GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase EC 2.4.1.309: UDP-Gal:α-L-Fuc-1,2-β-Gal-1,3-α-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.310: vancomycin aglycone glucosyltransferase EC 2.4.1.311: chloroorienticin B synthase EC 2.4.1.312: protein O-mannose β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.313: protein O-mannose β-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.314: ginsenoside Rd glucosyltransferase EC 2.4.1.315: diglucosyl diacylglycerol synthase (1,6-linking) EC 2.4.1.316: tylactone mycaminosyltransferase EC 2.4.1.317: O-mycaminosyltylonolide 6-deoxyallosyltransferase EC 2.4.1.318: demethyllactenocin mycarosyltransferase EC 2.4.1.319: β-1,4-mannooligosaccharide phosphorylase EC 2.4.1.320: 1,4-β-mannosyl-N-acetylglucosamine phosphorylase EC 2.4.1.321: cellobionic acid phosphorylase EC 2.4.1.322: devancosaminyl-vancomycin vancosaminetransferase EC 2.4.1.323: 7-deoxyloganetic acid glucosyltransferase EC 2.4.1.324: 7-deoxyloganetin glucosyltransferase EC 2.4.1.325: TDP-N-acetylfucosamine:lipid II N-acetylfucosaminyltransferase EC 2.4.1.326: aklavinone 7-L-rhodosaminyltransferase EC 2.4.1.327: aclacinomycin-T 2-deoxy-L-fucose transferase EC 2.4.1.328: erythronolide mycarosyltransferase EC 2.4.1.329: sucrose 6F-phosphate phosphorylase EC 2.4.1.330: β-D-glucosyl crocetin β-1,6-glucosyltransferase EC 2.4.1.331: 8-demethyltetracenomycin C L-rhamnosyltransferase EC 2.4.1.332: 1,2-α-glucosylglycerol phosphorylase EC 2.4.1.333: 1,2-β-oligoglucan phosphorylase EC 2.4.1.334: 1,3-α-oligoglucan phosphorylase EC 2.4.1.335: dolichyl N-acetyl-α-D-glucosaminyl phosphate 3-β-D-2,3-diacetamido-2,3-dideoxy-β-D-glucuronosyltransferase EC 2.4.1.336: monoglucosyldiacylglycerol synthase EC 2.4.1.337: 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.338: validoxylamine A glucosyltransferase EC 2.4.1.339: β-1,2-mannobiose phosphorylase EC 2.4.1.340: 1,2-β-oligomannan phosphorylase EC 2.4.1.341: α-1,2-colitosyltransferase EC 2.4.1.342: α-maltose-1-phosphate synthase EC 2.4.1.343: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.344: type 2 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.345: phosphatidyl-myo-inositol α-mannosyltransferase EC 2.4.1.346: phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.347: α,α-trehalose-phosphate synthase (ADP-forming) EC 2.4.1.348: N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.349: mannosyl-N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.350: mogroside IE synthase EC 2.4.1.351: rhamnogalacturonan I rhamnosyltransferase EC 2.4.1.352: glucosylglycerate phosphorylase EC 2.4.1.353: sordaricin 6-deoxyaltrosyltransferase EC 2.4.1.354: (R)-mandelonitrile β-glucosyltransferase EC 2.4.1.355: poly(ribitol-phosphate) β-N-acetylglucosaminyltransferase EC 2.4.1.356: glucosyl-dolichyl phosphate glucuronosyltransferase EC 2.4.1.357: phlorizin synthase EC 2.4.1.358: acylphloroglucinol glucosyltransferase EC 2.4.1.359: glucosylglycerol phosphorylase (configuration-retaining) EC 2.4.1.360: 2-hydroxyflavanone C-glucosyltransferase EC 2.4.1.361: GDP-mannose:di-myo-inositol-1,3′-phosphate β-1,2-mannosyltransferase EC 2.4.1.362: α-(1→3) branching sucrase EC 2.4.1.363: ginsenoside 20-O-glucosyltransferase EC 2.4.1.364: protopanaxadiol-type ginsenoside 3-O-glucosyltransferase EC 2.4.1.365: protopanaxadiol-type ginsenoside-3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.366: ginsenoside F1 6-O-glucosyltransferase EC 2.4.1.367: ginsenoside 6-O-glucosyltransferase EC 2.4.1.368: oleanolate 3-O-glucosyltransferase EC 2.4.1.369: enterobactin C-glucosyltransferase EC 2.4.1.370: inositol phosphorylceramide mannosyltransferase EC 2.4.1.371: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol 2,3-α-mannosylpolymerase EC 2.4.1.372: mutansucrase EC 2.4.1.373: α-(1→2) branching sucrase EC 2.4.1.374: β-1,2-mannooligosaccharide synthase EC 2.4.1.375: rhamnogalacturonan I galactosyltransferase EC 2.4.1.376: EGF-domain serine glucosyltransferase EC 2.4.1.377: dTDP-Rha:α-D-Gal-diphosphoundecaprenol α-1,3-rhamnosyltransferase EC 2.4.1.378: GDP-mannose:α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,4-mannosyltransferase EC 2.4.1.379: GDP-Man:α-D-Gal-diphosphoundecaprenol α-1,3-mannosyltransferase EC 2.4.1.380: GDP-Man:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-mannosyltransferase EC 2.4.1.381: dTDP-Rha:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-rhamnosyltransferase EC 2.4.1.382: CDP-abequose:α-L-Rha2OAc-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.383: GDP-Man:α-L-Rha-(1→3)-α-D-Gal-PP-Und β-1,4-mannosyltransferase EC 2.4.1.384: NDP-glycosyltransferase
Sources: en.wikipedia.org
Alogliptin (Figure 9) is a novel DPP-4 inhibitor developed by the Takeda Pharmaceutical Company. Researchers hypothesized that a quinazolinone based structure (Figure 9) would have the necessary groups to interact with the active site on the DPP-4 complex. Quinazolinone based compounds interacted effectively with the DPP-4 complex, but suffered from low metabolic half-life. It was found that when replacing the quinazolinone with a pyrimidinedione, the metabolic stability was increased and the result was a potent, selective, bioavailable DPP-4 inhibitor named alogliptin. The quinazoline based compounds showed potent inhibition and excellent selectivity over related protease, DPP-8. However, short metabolic half-life due to oxidation of the A-ring phenyl group was problematic. At first, the researchers tried to make a fluorinated derivative. The derivative showed improved metabolic stability and excellent inhibition of the DPP-4 enzyme. However, it was also found to inhibit CYP 450 3A4 and block the hERG channel. The solution to this problem was to replace the quinazolinone with other heterocycles, but the quinazolinone could be replaced without any loss of DPP-4 inhibition. Alogliptin was discovered when quinazolinone was replaced with a pyrimidinedione. Alogliptin has shown excellent inhibition of DPP-4 and extraordinary selectivity, greater than 10.000 fold over the closely related serine proteases DPP-8 and DPP-9. Also, it does not inhibit the CYP 450 enzymes nor block the hERG channel at concentration up to 30 μM.
Hemolytic disease of the newborn is an autoimmune disease resulting from the mother's antibodies crossing the placenta to the fetus. This most often occurs when the mother has previously been exposed to blood antigens present on the fetus but foreign to her, through either a blood transfusion or a previous pregnancy.
Through the early stages of the game, Combine Civil Protection units pursue Gordon Freeman, the player character, through City 17 after Gordon's presence is mistakenly revealed to Dr. Breen. Due to Gordon's actions in Half-Life and his subsequent disappearance, which earned him a legendary reputation, Dr. Breen sees Gordon as a significant threat. As Gordon flees the city, Civil Protection units raid the resistance base of Black Mesa East and capture resistance leader Eli Vance, who is transferred to holding facilities at Nova Prospekt. Gordon, along with Eli's daughter Alyx, breaks into the facility to rescue him, but Eli is teleported to the Combine Citadel by double agent Judith Mossman. The strike against Nova Prospekt prompts a revolution by the citizens of Earth and heavy street fighting takes place. In Episode One, the destruction of the teleporter has isolated Combine forces on Earth, and its primary reactor has begun to melt down. This forces Gordon and Alyx to journey back into the critically damaged Citadel to stabilize its reactor while the city's inhabitants are evacuated. The Combine forces, however, instead attempt to accelerate the meltdown in order to contact their native dimension for reinforcements. After Alyx acquires an encrypted copy of the message to be sent, Overwatch forces desperately attempt to stop the pair from escaping the city, spurred on by Combine Advisors. As the pair escape on a train at the end of the game, the Citadel detonates and destroys City 17.
==== Estrogen ==== Estrogens, together, make up a group of primary female sex hormones synthesized in the ovaries. See Estrogen: Brain and behavior for more on the role of estrogen in behavioral endocrinology.
Prior to its independence, the government of the Federation of Malaya was headed by a British high commissioner with executive powers, assisted and advised by the Federation of Malaya Executive Council and the Federation of Malaya Legislative Council.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.